Clinical Trial Detail

NCT ID NCT02681549
Title Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Yale University
Indications

melanoma

lung non-small cell carcinoma

Therapies

Bevacizumab + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.